Owens & Minor posts Q1 net loss $(0.32)/share; raises 2023 guidance on Patient Direct strength

ACCENDRA HEALTH INC/VA/

2023-Q1 EPS reported -$0.32 revenue$2,522,849,000

Revenue $2.5B (+4.8% YoY); GAAP net loss $24.4M vs. net income $39.3M in Q1 2022.
Adjusted EPS $0.05 vs. $0.96 prior year; adjusted operating income $47.7M vs. $104.9M.
Patient Direct segment drove margin expansion; Products & Healthcare Services saw destocking pressure.
Raised 2023 guidance: revenue $10.35-10.55B, adjusted EBITDA $480-510M (from $465-490M).
Generated $158M operating cash flow; paid down $117M debt in Q1.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACCENDRA HEALTH INC/VA/ reported the first quarter ended March 31, 2023 results: revenue $2,523, net income $(24.4), EPS $(0.32). Guidance raised.

Period: the first quarter ended March 31, 2023
Revenue: $2,523
Net income: $(24.4)
EPS: $(0.32)
Guidance: raised
Result: reported results

Exact text from the filing

Financial Summary (1) ($ in millions, except per share data) 1Q23 1Q22 Revenue $2,523 $2,407 Operating income, GAAP $9.8 $61.1 Adj. Operating Income, Non-GAAP $47.7 $104.9 Net (loss) income, GAAP $(24.4) $39.3 Adj. Net Income, Non-GAAP $3.6 $72.8 Adj. EBITDA, Non-GAAP $108.7 $122.6 Net (loss) income per common share, GAAP $(0.32) $0.52 Adj. Net Income per share, Non-GAAP $0.05 $0.96

View on SEC.gov

Browse all earnings releases →

ACCENDRA HEALTH INC/VA/ filing history →

Source: SEC EDGAR

accession 0000075252-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.